Today, in the on-line newsletter published by PharmaIQ, Cristina Falçao wrote in her column entitled “Ensuring a change for a better” an article on the necessary vital link between Big Pharma, translation and translators :

Big Pharma Cannot Afford to be Lost in Translation

Medical device growth is outpacing pharma industry. Europe accounts for about 30% of world revenues for medical equipment, the regulations for translation of medical devices in the EU affect a large portion of global device distribution; there are challenges in translation and communicating science in a multilingual world dominated by the de facto language of English. The EU alone has 23 mother tongues.

Since more and more clinical research and drug manufacturing are being done in multiple countries and in multiple languages, quality language services can help bring a drug to market faster, and can help streamline the clinical trial process. Translation may be required at many stages, including clinical research, regulatory submission and review, production and marketing. Moreover, expansion of the EU block into new member countries is also driving increased demand for medical and pharmaceutical translation services.

Technical translation is an art and a scientific process. Not understanding the crucial role of a technical translator is running blind in terms of competitive advantage; this person will be the ultimate responsible for the company’s bottom line – without a proper translation, no drug or medical device will have Marketing authorization. More.

See : Pharma IQ